Sponsors (6)
The bill improves understanding, transparency, and potential clinical and service responses to veteran suicide but imposes administrative costs and privacy and reputational risks that could divert resources or harm stakeholders if not carefully managed.
Veterans — their deaths by suicide will be systematically reviewed, producing clearer counts and context about causes and contributing factors.
Veterans and VA patients — the review findings could prompt improved prescribing oversight and clinical coordination that reduce overprescribing and medication-related risk.
Veterans and people needing mental health care — reporting on availability and staffing of counselors and therapists could drive hiring and training that expand access to non-medication first‑line treatments.
Taxpayers and veterans — conducting mandated reviews will require substantial VA and NAS resources and staff time, imposing administrative costs and potentially diverting resources from other veteran services.
Veterans and people with disabilities — detailed public reporting of decedents' demographics and toxicology increases the risk of privacy harms or re‑identification if de‑identification is inadequate.
Hospitals, clinics, staff and patients — identifying high‑prescribing facilities could cause reputational harm or legal scrutiny before causation is established.
Based on analysis of 2 sections of legislative text.
Directs VA to commission a National Academies review of suicides among defined veterans over the prior five years, compiling toxicology, prescriptions, diagnoses, and treatment‑pattern analyses.
Introduced January 3, 2025 by Vernon G. Buchanan · Last progress January 3, 2025
Requires the Secretary of Veterans Affairs to contract with the National Academies to review suicides among a defined group of veterans over the five years before enactment, and to report detailed findings about medications, toxicology, diagnoses, prescribing patterns, and use of non‑medication treatments. The Department must produce counts and comparative analyses (e.g., medication-only vs. non-medication first-line care), describe guideline development and use of VA tools (such as the Pain as the 5th Vital Sign Toolkit), and provide demographic and prescription-level toxicology detail for the covered decedents.